Pharmesis International (SGX:BFK) Stock Based Compensation: S$0.00 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SGX:BFK Pharmesis International Ltd SGX:BFK
34 GF Score
Price S$0.13
GF Value S$0.16
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Pharmesis International Stock Based Compensation?

Pharmesis International SGX:BFK 34 Stock Based Compensation is S$0.00 Mil as of Jun. 2026. GuruFocus rates SGX:BFK with a GF Score™ of 34/100 and a GF Value™ of S$0.16 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Pharmesis International's Stock Based Compensation for the six months ended in Jun. 2026 was S$0.00 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2026 was S$0.00 Mil.

Pharmesis International Stock Based Compensation Related Terms

Pharmesis International Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Pharmesis International's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmesis International Stock Based Compensation Chart

Pharmesis International Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Pharmesis International Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
SGX:BFK
34GF Score
Pharmesis International Ltd SGX:BFK
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharmesis International Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was S$0.00 Mil.

What does a Stock Based Compensation of S$0.00 Mil mean?
Pharmesis International (SGX:BFK) has a Stock Based Compensation of S$0.00 Mil as of Jun. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Pharmesis International and its competitors.
Is Pharmesis International's Stock Based Compensation too high?
Pharmesis International's current Stock Based Compensation is S$0.00 Mil. Overall, Pharmesis International has a GF Score™ of 34/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharmesis International's Stock Based Compensation compare to ZTS and UTHR?
Pharmesis International's Stock Based Compensation of S$0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Drug Manufacturers company?
A good Stock Based Compensation depends on the Drug Manufacturers industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Pharmesis International and its competitors. Pharmesis International's current Stock Based Compensation is S$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmesis International stock overvalued right now?
Based on GuruFocus' analysis, Pharmesis International (SGX:BFK) is currently considered Modestly Undervalued. The stock's GF Value™ is S$0.16, compared to a current price of S$0.13 — trading 21.9% below its estimated fair value. The current Stock Based Compensation is S$0.00 Mil. Pharmesis International's overall GF Score™ is 34/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Pharmesis International (SGX:BFK), the current Stock Based Compensation is S$0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharmesis International (SGX:BFK) Overvalued in 2026?

Based on GuruFocus' analysis, Pharmesis International stock appears to be undervalued. The current stock price of S$0.13 is trading 21.9% below its estimated GF Value™ of S$0.16. GuruFocus considers Pharmesis International to be Modestly Undervalued.

Key valuation signals for SGX:BFK:

  • Stock Based Compensation: S$0.00 Mil
  • GF Value™: S$0.16 vs. price of S$0.13 (21.9% below fair value)
  • GF Score™: 34/100 with 6 warning signs

No single metric tells the full story. See the SGX:BFK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharmesis International Business Description

Address 5 Kallang Sector, No. 03-02, Singapore, SGP, 349279
Pharmesis International Ltd is an investment holding company. The company manufactures pharmaceutical products in the form of tablets, granules, pills, and other forms. Its operating segments are Western drugs/TCH Procurement, which are chemically formulated drugs and are marketed under the Kinna brand; TCM-formulated drugs/IP rental, which refer to Traditional Chinese Medicine and are marketed under the Longlife brand; and Distribution, which derives maximum revenue, refers to agency products and internally manufactured products which are marketed through the distribution arm. The company derives revenue from the sale of medicines to domestic customers in China.
34GF Score

Get the complete analysis for SGX:BFK

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

S$0.13
Price
S$0.16
GF Value